Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
Beximco Pharmaceuticals Limited (BXP) - Total Liabilities
Latest total liabilities as of December 2024: GBX20.17 Billion GBX
Based on the latest financial reports, Beximco Pharmaceuticals Limited (BXP) has total liabilities worth GBX20.17 Billion GBX as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beximco Pharmaceuticals Limited - Total Liabilities Trend (2005–2024)
This chart illustrates how Beximco Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Beximco Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Beximco Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DUET Acquisition Corp. Warrant
NASDAQ:DUETW
|
USA | $8.26 Million |
|
MS INTERNATIONAL plc
LSE:MSI
|
UK | GBX72.95 Million |
|
CHINA LIFE INS -H-
HM:CHL
|
Germany | €5.90 Trillion |
|
Caspian Services Inc
PINK:CSSV
|
USA | $117.03 Million |
|
NIOX Group PLC
LSE:NIOX
|
UK | GBX6.60 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Beximco Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beximco Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beximco Pharmaceuticals Limited (2005–2024)
The table below shows the annual total liabilities of Beximco Pharmaceuticals Limited from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | GBX17.44 Billion | -19.02% |
| 2023-06-30 | GBX21.54 Billion | +0.12% |
| 2022-06-30 | GBX21.51 Billion | +44.56% |
| 2021-06-30 | GBX14.88 Billion | -14.09% |
| 2020-06-30 | GBX17.32 Billion | -10.48% |
| 2019-06-30 | GBX19.35 Billion | +18.08% |
| 2018-06-30 | GBX16.39 Billion | +81.84% |
| 2017-06-30 | GBX9.01 Billion | +11.40% |
| 2016-06-30 | GBX8.09 Billion | -3.20% |
| 2015-12-31 | GBX8.36 Billion | +3.42% |
| 2014-12-31 | GBX8.08 Billion | +5.00% |
| 2013-12-31 | GBX7.70 Billion | +24.48% |
| 2012-12-31 | GBX6.18 Billion | +4.68% |
| 2011-12-31 | GBX5.91 Billion | +9.39% |
| 2010-12-31 | GBX5.40 Billion | -40.06% |
| 2009-12-31 | GBX9.01 Billion | +106.11% |
| 2008-12-31 | GBX4.37 Billion | +18.02% |
| 2007-12-31 | GBX3.70 Billion | -6.57% |
| 2006-12-31 | GBX3.96 Billion | -3.93% |
| 2005-12-31 | GBX4.12 Billion | -- |